ALC vs INDV
Alcon Inc vs Indivior Pharmaceuticals Inc — AI-powered side-by-side comparison
VS
INDV
Indivior Pharmaceuticals Inc
58
Watch
| Metric | ALC | INDV |
|---|
| AI Score |
68
|
58
|
| Price |
$75.39
|
$38.42
|
| P/E Ratio |
45.39×
|
13.53×
|
| ROE |
4.4%
|
-214.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
83.9%
|
| Debt / Equity |
0.24×
|
-2.45×
|
| Dividend Yield |
0.5%
|
0.0%
|
| RSI (14) |
73.4
|
42.6
|
| Beta |
0.703
|
1.0251
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus INDV.
ALC leads by 10 points.
ALC scores 68/100 (Buy) versus INDV at 58/100 (Watch).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
INDV Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — high leverage (debt-to-equity 5.43) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- P/E of 12.8 is inexpensive for the broad market — Value
- ROE of 159.1% shows genuine earnings power backing the valuation — Value
- EPS growing 237.5% YoY — Growth
Bear Case
- Price-to-book of 49.6x prices in significant intangible value — Value
- Debt-to-equity of 5.43 adds balance-sheet risk to the value case — Value
- MACD histogram negative -- bearish momentum — Technical